Improving HIV-1 Control in Africa With Long Acting Antiretrovirals

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically suppressed HIV-1 infected adults who have a history of sub-optimal adherence to daily oral ART and/or engagement in HIV care. The study will seek to demonstrate non-inferior antiviral effectiveness of the 2-monthly long-acting injectable combination of cabotegravir/rilpivirine as compared to continuation of first line oral antiretroviral therapy.
Epistemonikos ID: d83c76fcda2a660f6d0ac7e8966555aba54633f0
First added on: May 13, 2024